Barclays’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-16,128
| Closed | -$13.3K | – | 5412 |
|
|
2025
Q1 | $13.3K | Hold |
16,128
| – | – | ﹤0.01% | 4840 |
|
|
2024
Q4 | $15.3K | Hold |
16,128
| – | – | ﹤0.01% | 4952 |
|
|
2024
Q3 | $16.1K | Hold |
16,128
| – | – | ﹤0.01% | 4922 |
|
|
2024
Q2 | $20K | Hold |
16,128
| – | – | ﹤0.01% | 4436 |
|
|
2024
Q1 | $21K | Hold |
16,128
| – | – | ﹤0.01% | 4749 |
|
|
2023
Q4 | $20.2K | Hold |
16,128
| – | – | ﹤0.01% | 4905 |
|
|
2023
Q3 | $21K | Hold |
16,128
| – | – | ﹤0.01% | 4168 |
|
|
2023
Q2 | $27.7K | Sell |
16,128
-23,559
| -59% | -$37.4K | ﹤0.01% | 4064 |
|
|
2023
Q1 | $57.9K | Buy |
39,687
+12,634
| +47% | +$24.2K | ﹤0.01% | 4399 |
|
|
2022
Q4 | $43.8K | Buy |
27,053
+9,200
| +52% | +$21.2K | ﹤0.01% | 4595 |
|
|
2022
Q3 | $60K | Sell |
17,853
-2,024
| -10% | -$9.14K | ﹤0.01% | 3724 |
|
|
2022
Q2 | $72K | Buy |
19,877
+9,609
| +94% | +$43.6K | ﹤0.01% | 3906 |
|
|
2022
Q1 | $77K | Buy |
+10,268
| New | +$87.6K | ﹤0.01% | 3912 |
|
Barclays's KRON Position: Q2 2025 in Review
Barclays sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 16,128 shares — an estimated $13.3K sold.
Barclays first reported a position in KRON in Q1 2022 and held it in 13 quarters. The position peaked at $77K in Q1 2022. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Barclays reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Barclays sold 16,128 Kronos Bio shares in Q2 2025, an estimated $13.3K.
- Barclays first reported a position in Kronos Bio in Q1 2022 and held it in 13 quarters.
- Barclays's Kronos Bio position peaked at $77K in Q1 2022.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.